- Home
- DMA vs VRCA Comparison
DMA vs VRCA Comparison
Compare DMA & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMA | VRCA |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 87.5M |
| IPO Year | 2011 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DMA | VRCA |
|---|---|---|
| Price | $7.43 | $7.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 27.7K | ★ 88.7K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $94.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $7.27 | $0.47 |
| 52 Week High | $9.15 | $9.82 |
Technical Indicators
Market Signals| Indicator | DMA | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 30.27 | 60.30 |
| Support Level | $7.27 | $7.24 |
| Resistance Level | $8.89 | $8.24 |
| Average True Range (ATR) | 0.22 | 0.56 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 10.58 | 58.09 |
Price Performance
Historical ComparisonAbout DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.